DK1651621T3 - 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer - Google Patents
2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorerInfo
- Publication number
- DK1651621T3 DK1651621T3 DK04780055T DK04780055T DK1651621T3 DK 1651621 T3 DK1651621 T3 DK 1651621T3 DK 04780055 T DK04780055 T DK 04780055T DK 04780055 T DK04780055 T DK 04780055T DK 1651621 T3 DK1651621 T3 DK 1651621T3
- Authority
- DK
- Denmark
- Prior art keywords
- ylsulfonylamino
- quinoxaline
- benzamide compounds
- cck2
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Structural Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49407403P | 2003-08-08 | 2003-08-08 | |
| PCT/US2004/025153 WO2005016896A1 (en) | 2003-08-08 | 2004-08-04 | 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1651621T3 true DK1651621T3 (da) | 2008-11-10 |
Family
ID=34193199
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04780055T DK1651621T3 (da) | 2003-08-08 | 2004-08-04 | 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer |
| DK04780056T DK1651622T3 (da) | 2003-08-08 | 2004-08-04 | Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04780056T DK1651622T3 (da) | 2003-08-08 | 2004-08-04 | Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7288651B2 (xx) |
| EP (2) | EP1651621B1 (xx) |
| JP (2) | JP2007501842A (xx) |
| KR (1) | KR20060060007A (xx) |
| CN (2) | CN1863782A (xx) |
| AR (1) | AR045930A1 (xx) |
| AT (2) | ATE403650T1 (xx) |
| AU (2) | AU2004265312B2 (xx) |
| BR (1) | BRPI0413449A (xx) |
| CA (2) | CA2534885C (xx) |
| CR (1) | CR8229A (xx) |
| CY (1) | CY1106486T1 (xx) |
| DE (2) | DE602004015614D1 (xx) |
| DK (2) | DK1651621T3 (xx) |
| EA (1) | EA200600203A1 (xx) |
| EC (1) | ECSP066355A (xx) |
| ES (2) | ES2310294T3 (xx) |
| HR (1) | HRP20080559T3 (xx) |
| IL (1) | IL173591A0 (xx) |
| IS (1) | IS8280A (xx) |
| LT (1) | LT5410B (xx) |
| LV (1) | LV13453B (xx) |
| MX (2) | MXPA06001550A (xx) |
| NO (1) | NO20061122L (xx) |
| NZ (1) | NZ545030A (xx) |
| PL (2) | PL1651621T3 (xx) |
| PT (2) | PT1651622E (xx) |
| SG (1) | SG131114A1 (xx) |
| SI (2) | SI1651621T1 (xx) |
| TW (1) | TW200521120A (xx) |
| UA (1) | UA84025C2 (xx) |
| WO (2) | WO2005016896A1 (xx) |
| ZA (1) | ZA200601946B (xx) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200600203A1 (ru) * | 2003-08-08 | 2006-08-25 | Янссен Фармацевтика, Н. В. | Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2 |
| WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
| EP1763524A1 (en) * | 2004-04-23 | 2007-03-21 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| US7947833B2 (en) * | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| AU2005289887A1 (en) * | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
| FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| US8592565B2 (en) * | 2007-01-12 | 2013-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Preparation of azide-modified carbon surfaces for coupling to various species |
| EP2123644B1 (en) * | 2007-03-07 | 2014-12-17 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| WO2008124518A1 (en) * | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor |
| EP2131243B1 (en) * | 2008-06-02 | 2015-07-01 | ASML Netherlands B.V. | Lithographic apparatus and method for calibrating a stage position |
| US8354557B2 (en) * | 2008-06-17 | 2013-01-15 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| WO2010118208A1 (en) * | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| JP5890312B2 (ja) | 2009-10-09 | 2016-03-22 | ザフゲン，インコーポレイテッド | 肥満治療に用いられるスルホン化合物 |
| WO2012004604A1 (en) | 2010-07-09 | 2012-01-12 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
| AU2011281037B2 (en) | 2010-07-22 | 2014-11-27 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| US9321740B2 (en) | 2011-01-26 | 2016-04-26 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| AU2012253759B2 (en) | 2011-05-06 | 2016-01-21 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| EA025526B1 (ru) | 2011-05-06 | 2017-01-30 | Зафджен Инк. | Частично насыщенные трициклические соединения и способы их получения и применения |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| EP2804856B1 (en) | 2012-01-18 | 2017-03-15 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| KR20140112565A (ko) | 2012-01-18 | 2014-09-23 | 자프겐 인크. | 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
| SI2820010T1 (sl) * | 2012-03-01 | 2018-11-30 | Allergan, Inc. | Derivati benzofuran-2-sulfonamida kot modulatorji kemokinskih receptorjev |
| BR112015010196A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | métodos de tratar doença do fígado |
| JP2015536983A (ja) | 2012-11-05 | 2015-12-24 | ザフゲン，インコーポレイテッド | 肥満の治療及び抑制における三環式化合物の使用 |
| CA2890342A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| JP6361168B2 (ja) * | 2013-06-17 | 2018-07-25 | Jsr株式会社 | 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物 |
| CN103524386B (zh) * | 2013-10-24 | 2016-05-18 | 江苏鼎龙科技有限公司 | 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法 |
| BR112016011727A2 (pt) | 2013-11-22 | 2017-08-08 | CL BioSciences LLC | Antagonistas de gastrina para o tratamento e prevenção de osteoporose |
| KR20170016754A (ko) * | 2015-08-04 | 2017-02-14 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN106565509A (zh) * | 2016-11-03 | 2017-04-19 | 江苏鼎龙科技有限公司 | 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法 |
| KR101894091B1 (ko) | 2018-01-23 | 2018-08-31 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN108218806B (zh) * | 2018-04-02 | 2019-03-01 | 上海馨远医药科技有限公司 | 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法 |
| CN111285806B (zh) * | 2018-12-06 | 2022-04-15 | 中国医学科学院药物研究所 | 吡唑类化合物及其制备方法、用途和药物组合物 |
| CN116675684B (zh) * | 2023-08-02 | 2023-11-07 | 上海翰森生物医药科技有限公司 | 含炔基稠环类衍生物拮抗剂、其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200420D0 (en) * | 1992-01-09 | 1992-02-26 | James Black Foundation The Lim | Amino acid derivatives |
| HU222178B1 (hu) * | 1993-08-10 | 2003-04-28 | James Black Foundation Ltd. | Gasztrin és CCK-receptor ligandumok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények |
| DE69724644D1 (de) | 1996-12-10 | 2003-10-09 | Zeria Pharm Co Ltd | 1,5-benzodiazepinderivate |
| DE10121002A1 (de) | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121003A1 (de) | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10134721A1 (de) * | 2001-07-17 | 2003-02-06 | Bayer Ag | Tetrahydrochinoxaline |
| ITTO20020674A1 (it) | 2002-07-26 | 2004-01-26 | Rotta Research Lab | Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico |
| US6943170B2 (en) * | 2002-11-14 | 2005-09-13 | Bristol-Myers Squibb Company | N-cycloalkylglycines as HIV protease inhibitors |
| EA200600203A1 (ru) * | 2003-08-08 | 2006-08-25 | Янссен Фармацевтика, Н. В. | Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2 |
| AU2005289887A1 (en) * | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
-
2004
- 2004-08-04 EA EA200600203A patent/EA200600203A1/ru unknown
- 2004-08-04 ES ES04780055T patent/ES2310294T3/es active Active
- 2004-08-04 PT PT04780056T patent/PT1651622E/pt unknown
- 2004-08-04 EP EP04780055A patent/EP1651621B1/en active Active
- 2004-08-04 DK DK04780055T patent/DK1651621T3/da active
- 2004-08-04 CA CA2534885A patent/CA2534885C/en active Active
- 2004-08-04 SG SG200701706-4A patent/SG131114A1/en unknown
- 2004-08-04 NZ NZ545030A patent/NZ545030A/en unknown
- 2004-08-04 UA UAA200601931A patent/UA84025C2/ru unknown
- 2004-08-04 CN CNA200480029094XA patent/CN1863782A/zh active Pending
- 2004-08-04 DK DK04780056T patent/DK1651622T3/da active
- 2004-08-04 SI SI200430901T patent/SI1651621T1/sl unknown
- 2004-08-04 CN CNA2004800290901A patent/CN1863781A/zh active Pending
- 2004-08-04 JP JP2006523231A patent/JP2007501842A/ja not_active Withdrawn
- 2004-08-04 BR BRPI0413449-4A patent/BRPI0413449A/pt not_active IP Right Cessation
- 2004-08-04 AU AU2004265312A patent/AU2004265312B2/en not_active Expired - Fee Related
- 2004-08-04 CA CA002534887A patent/CA2534887A1/en not_active Abandoned
- 2004-08-04 AT AT04780055T patent/ATE403650T1/de not_active IP Right Cessation
- 2004-08-04 AT AT04780056T patent/ATE353322T1/de not_active IP Right Cessation
- 2004-08-04 PT PT04780055T patent/PT1651621E/pt unknown
- 2004-08-04 WO PCT/US2004/025153 patent/WO2005016896A1/en active IP Right Grant
- 2004-08-04 AU AU2004265311A patent/AU2004265311A1/en not_active Abandoned
- 2004-08-04 ES ES04780056T patent/ES2281834T3/es active Active
- 2004-08-04 US US10/910,983 patent/US7288651B2/en active Active
- 2004-08-04 DE DE602004015614T patent/DE602004015614D1/de active Active
- 2004-08-04 EP EP04780056A patent/EP1651622B1/en active Active
- 2004-08-04 PL PL04780055T patent/PL1651621T3/pl unknown
- 2004-08-04 KR KR1020067002650A patent/KR20060060007A/ko not_active Application Discontinuation
- 2004-08-04 MX MXPA06001550A patent/MXPA06001550A/es active IP Right Grant
- 2004-08-04 JP JP2006523230A patent/JP4818110B2/ja not_active Expired - Fee Related
- 2004-08-04 US US10/910,925 patent/US7304051B2/en active Active
- 2004-08-04 DE DE602004004663T patent/DE602004004663T2/de active Active
- 2004-08-04 WO PCT/US2004/025154 patent/WO2005016897A1/en active IP Right Grant
- 2004-08-04 PL PL04780056T patent/PL1651622T3/pl unknown
- 2004-08-04 SI SI200430245T patent/SI1651622T1/sl unknown
- 2004-08-04 MX MXPA06001482A patent/MXPA06001482A/es active IP Right Grant
- 2004-08-06 TW TW093123552A patent/TW200521120A/zh unknown
- 2004-08-06 AR ARP040102814A patent/AR045930A1/es not_active Application Discontinuation
-
2006
- 2006-01-31 IS IS8280A patent/IS8280A/is unknown
- 2006-02-07 IL IL173591A patent/IL173591A0/en unknown
- 2006-02-08 EC EC2006006355A patent/ECSP066355A/es unknown
- 2006-02-08 LV LVP-06-18A patent/LV13453B/en unknown
- 2006-02-08 CR CR8229A patent/CR8229A/es unknown
- 2006-03-07 LT LT2006017A patent/LT5410B/lt not_active IP Right Cessation
- 2006-03-07 ZA ZA200601946A patent/ZA200601946B/en unknown
- 2006-03-08 NO NO20061122A patent/NO20061122L/no not_active Application Discontinuation
-
2007
- 2007-04-04 CY CY20071100473T patent/CY1106486T1/el unknown
- 2007-12-04 US US11/950,326 patent/US7563895B2/en active Active
-
2008
- 2008-11-03 HR HR20080559T patent/HRP20080559T3/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1651621T3 (da) | 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer | |
| IS8323A (is) | Ný amínóbensófenónefnasambönd | |
| NO20052884D0 (no) | Substituerte indolpyridinforbindelser som anti-infeksjonsmidler. | |
| IS7471A (is) | Ný efnasambönd | |
| IS7879A (is) | Ný efnasambönd | |
| SE0301569D0 (sv) | Novel compounds | |
| IS8108A (is) | Ný efnasambönd | |
| DK1817309T3 (da) | Acetamidforbindelser som fungicider | |
| ATE368042T1 (de) | Cephemverbindungen | |
| IS8228A (is) | Ný asetídínefnasambönd | |
| IS7381A (is) | Efnasambönd | |
| IS7414A (is) | Oxó-azabísýklísk efnasambönd | |
| NO20035571D0 (no) | N-formyl hydroksylaminforbindelser som PDF-inhibitorer | |
| IS7943A (is) | Ný amínóbensófenónefnasambönd | |
| DK1569892T3 (da) | Kalcilytiske forbindelser | |
| SE0303452D0 (sv) | New compounds | |
| SE0203348D0 (sv) | Novel compounds | |
| NO20043743L (no) | Karboksylsyreforbindelser for anvendelse som overflateaktive midler | |
| DK1210333T3 (da) | p-Tolylsubstituerede heterocycliske forbindelser som herbicider | |
| SE0201981D0 (sv) | Novel compounds | |
| SE0201636D0 (sv) | Novel compounds | |
| SE0200118D0 (sv) | Novel compounds | |
| SE0200117D0 (sv) | Novel compounds | |
| SE0202908D0 (sv) | New compounds | |
| SE0200523D0 (sv) | New compounds |